Science & Technology

SBIR Phase II: Antibody-Drug Conjugates (ADCs) with High Drug-Antibody Ratios (DAR) and Molecularly Targeted Payloads

National Science Foundation

Opportunity #: 2423415

Award Ceiling

$1.0M

Award Floor

$1.0M

Close Date

Jun 30, 2027

472 days left

Total Funding

$1.0M

Expected Awards

Posted Date

Jul 15, 2025

Cost Sharing Required

Grants.gov ID

sbir-2423415

Description

SBIR Phase Phase II award: "SBIR Phase II: Antibody-Drug Conjugates (ADCs) with High Drug-Antibody Ratios (DAR) and Molecularly Targeted Payloads" awarded to WINDOW THERAPEUTICS, INC. in BOSTON, Massachusetts. Funded by National Science Foundation. Award amount: $1,000,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.